Is a Lung Transplant Linked to Longer Survival in Advanced Lung Cancer?

Is a lung transplant linked to longer survival in advanced lung cancer?

Yes, early on, in carefully selected patients. In this registry study, a lung transplant for advanced lung cancer confined to the lungs was associated with 100 percent survival at one year, compared with 40.8 percent for similar patients who received medical management alone. Longer follow-up is still needed.

That is a startling gap, and it comes from a group of people who had run out of options. All of them had stage IV non-small cell lung cancer that no longer responded to treatment. The one unusual thing about them was where the cancer sat. It had spread within the lungs, but it had not traveled anywhere else in the body. No liver, no bones, no brain. For most of these patients, the thing that was going to kill them was not cancer spreading. It was their lungs failing.

That raises an old and slightly radical idea. If the disease is trapped inside one organ, and that organ can be replaced, what happens if you simply take the organ out?

What the data show

Doctors at Northwestern Medicine followed 98 adults in exactly this situation. Seventeen of them received a lung transplant. The other 81 met the transplant criteria but did not get one because of nonbiologic barriers, and they continued with medical management alone, which usually means chemotherapy, immune therapy, or targeted drugs.

The survival difference was large. Using Kaplan-Meier estimates, which is a standard way of tracking survival over time, one-year overall survival was 100 percent in the transplant group and 40.8 percent in the group that stayed on medical management. In other words, roughly six of every ten patients on medical management had died within a year, while every transplant patient was still alive.

The transplant patients also did about as well as people who get lung transplants for reasons that have nothing to do with cancer. The same team compared them to 306 patients transplanted for end-stage lung disease, and the cancer group held up. That matters, because it suggests these patients were not unusually fragile and were not being ruined by the surgery itself.

By the end of extended follow-up in January 2026, 2 of the 17 transplant patients had died.

Dr. Kumar’s Take

This result calls for both interest and caution.

Stage IV lung cancer that has stopped responding to treatment is generally a terminal diagnosis measured in months. A 100 percent one-year survival number in that setting is unusual. The theory the researchers are testing is simple: if the disease truly lives only in the lungs, taking out the lungs takes out the disease.

The caution is just as important. Seventeen patients is a small number, and the 100 percent figure has a wide margin of error, from 63 to 100 percent. These were not average lung cancer patients, they were the rare few whose cancer stayed put, and someone made a careful judgment call about each one. The comparison group was not randomly assigned, so the people who got transplants may have been healthier or luckier in ways that are hard to measure. And a transplant is not a light thing. It means a lifetime of drugs that hold your immune system down, which is a strange bargain when the disease you are treating is cancer.

So I would call this a real signal, not a settled answer. It is the kind of result that should open a door, carefully, rather than swing it wide.

Who this actually applies to

Almost nobody with lung cancer will be a candidate for this, and it is worth being blunt about that. The whole approach depends on one narrow condition: the cancer must be confined to the lungs and nowhere else. Once tumor cells have set up shop in the bones or the brain or the liver, removing the lungs removes only part of the problem, and the rest keeps growing.

Patients also have to be well enough to survive a major operation and to tolerate the anti-rejection medications afterward. That combination, sick enough to need new lungs but strong enough to receive them, with cancer that has politely stayed in one place, describes a very small group of people.

How confident can you be?

This was a registry study, not a randomized trial. The researchers watched what happened to patients rather than flipping a coin to decide who got a transplant. That design cannot fully separate the effect of the transplant from the effect of being the kind of patient who gets offered one.

The follow-up is also still young for a cancer question. The median follow-up for transplant patients was just under a year, and nobody yet knows what the numbers look like at five or ten years. The authors themselves call for longer follow-up and quality-of-life data. What the study does show is that the operation was survivable in this population and that early survival was favorable compared with eligible patients who stayed on medical management. Confirming it will take more centers, more patients, and more time.

Practical Takeaways

If you or a family member has stage IV non-small cell lung cancer, ask the oncology team whether imaging shows the disease is confined to the lungs, because that single fact is what makes this option even thinkable.
Treat this as an option to discuss at a major transplant center, not something a general oncology clinic can arrange, since selection is strict.
Understand the trade before hoping for it, as a lung transplant means lifelong immune-suppressing drugs, frequent monitoring, and real surgical risk.
Do not read this as a reason to delay or skip standard treatment, because transplant was only considered here after other therapies had already failed.

FAQs

Why was lung transplant for cancer considered off-limits for so long?

The fear was that anti-rejection drugs would let any leftover cancer explode. Those drugs work by holding the immune system back so the body does not attack the new organ, and a suppressed immune system is theoretically worse at policing tumor cells. Transplant programs also worried about giving a scarce donor organ to someone likely to relapse quickly, since there are never enough lungs for everyone on the waiting list. This study does not erase those concerns, but it does show that in a tightly selected group, the feared disaster did not happen in the first year.

Does the cancer ever come back after the new lungs are in?

It can. Scans can miss small groups of tumor cells outside the lungs, and anti-rejection drugs weaken the immune system’s ability to keep them in check. Follow-up in this study was short, a median of just under a year for the transplant patients, and by January 2026 two of the 17 had died. Longer follow-up is needed to know how often the cancer returns.

How is this different from surgery that removes part of a lung?

Standard lung cancer surgery takes out a tumor and some surrounding tissue, and it is normally reserved for earlier-stage disease where the cancer sits in one spot. The patients in this study had cancer that had spread within the lungs and were in respiratory failure, which puts ordinary surgery off the table. A transplant sidesteps that by removing the diseased lung tissue and supplying new lungs to breathe with. The trade is that you exchange a cancer problem for a transplant problem, including a lifetime of medication.

Bottom Line

In a small Northwestern registry of patients with treatment-refractory stage IV lung cancer that had stayed inside the lungs, a lung transplant was associated with 100 percent one-year survival, compared with 40.8 percent for eligible patients who received medical management alone. By January 2026, 2 of the 17 transplant patients had died. This is 17 people, not a randomized trial, so it is not proof. The authors describe early survival as favorable and call for longer follow-up and quality-of-life data. It supports a simple idea worth testing further: when a cancer stays inside one organ, replacing that organ may take the cancer with it.

Read the full study